Heartseed Inc.

NEWS

Media Heartseed Selected to Be Featured in U.S. Public Service Announcement (PSA) Series Breakthroughs™

PR 52-Week Topline Results of Phase I/II Clinical Trial (LAPiS study) for Allogeneic iPS cell-derived Cardiomyocyte Spheroids (HS-001) Presented in Invited Lecture at ESC Congress 2026

Congress Keiichi Fukuda, CEO, to Present 52-Week Topline Results from the LAPiS Study in an Invited Lecture at the ESC Congress 2026

PR Heartseed, World's First Clinical Trial of Catheter Administration of iPSC-Derived Cardiomyocyte Spheroids: First Patient Dosed

Congress Keiichi Fukuda, CEO, to Speak at the 10th Cardiovascular Bioengineering (CVBE) Symposium 2026

PR Notice Regarding Selection as a Constituent of the JPX Start-Up Acceleration 100 Index

Seminar Keiichi Fukuda, CEO, to Speak at The 21st Edition of Roundtable Japan

Congress Keiichi Fukuda, CEO, to Speak at Keystone Symposia "iPSCs: Progress, Opportunities, and Challenges"

Congress Heartseed CMO Takehiko Kaneko to Speak at ISSCR International Symposium "PSC-Derived Therapies"

Congress Heartseed CMO Takehiko Kaneko to Speak at Global CVCT Forum - Discussing Clinical Trial Designs and Endpoints for Cell Therapy in Heart Failure -

1 2 3 4 5 6 7 8 9